Orladeyo (Berotralstat)

Berotralstat works by inhibiting plasma kallikrein, an enzyme that generates bradykinin. By reducing bradykinin production, the drug decreases vascular permeability and prevents the swelling episodes that characterize hereditary angioedema.

The dosage of Orladeyo is individualized by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response. The prescriber determines the appropriate dose and dosing schedule.

Safety data for berotralstat in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Orladeyo is an oral plasma kallikrein inhibitor, offering a convenient once‑daily tablet compared with injectable C1‑esterase inhibitor concentrates or monoclonal antibodies. Its oral route may improve adherence, while efficacy and safety profiles are comparable to other approved prophylactic agents.

Store Orladeyo tablets at ambient temperature, below 25 °C, in the original blister pack to protect from moisture. Keep the medication out of reach of children and avoid exposure to direct sunlight or extreme humidity.

Orladeyo is taken orally as a whole tablet with water. It is usually taken once daily, preferably at the same time each day, and can be taken with or without food unless otherwise directed by the prescriber.

Serious risks include potential liver enzyme elevations, rare cases of severe angioedema involving the airway, and hypersensitivity reactions such as anaphylaxis. Patients should be monitored for signs of liver dysfunction and any sudden swelling, and seek immediate medical attention if these occur.

Orladeyo is contraindicated in patients with severe hepatic impairment and in individuals who have demonstrated hypersensitivity to berotralstat or any of the tablet’s excipients. Caution is also advised for patients taking strong CYP3A4 inhibitors.